EmblemHealth Challenges Alexion’s Soliris Patent Practices in Federal Court Appeal
EmblemHealth is making a significant legal move in its ongoing dispute with AstraZeneca’s unit Alexion Pharmaceuticals. The nonprofit insurer has petitioned a federal judge in Massachusetts to allow an appeal to the First Circuit. This appeal challenges a decision that significantly reduced the scope of its class action suit, alleging that Alexion utilized questionable patent…